Drug products: Eldepryl®, Emsam, EMSAM, Selegilin Mylan
ATC code: N04BD01
Substances: selegiline, selegiline hydrochloride
Published controlled studies on differences between men and women regarding the effect of selegline are lacking. Pharmacokinetic studies have not shown any sex differences.
The reported incidence and prevalence of Parkinson’s disease (PD) is slightly higher in men than in women. It seems that men develop PD earlier in life compared to women. Several possible explanations behind these sex differences have been suggested; the protective role of estrogens in premenopausal women, and different profiles of risk factors (environmental and/or genetic). Sex differences in clinical presentations of PD have also been reported. Since the activities of daily living might differ between men and women with PD, different treatment strategies can be recommended to men and women with PD .
One review found no sex-related difference in the pharmacokinetics of selegiline following a single oral dose of selegiline 10 mg to six elderly men and six elderly women (age 60-85 years) . No studies with a clinically relevant sex analysis regarding the dosing of selegiline have been found.
No studies with a clinically relevant sex analysis regarding the effects of selegiline have been found.
The increased risk of impulse control disorder with use of dopamine agonists is well known [2-6]. One observational study on dopamine agonists (n=642, approx. 2/3 men) reports a higher frequency of impulse control disorder in men compared to women in patients using dopamine agonists .
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2020-05-08
Reviewed by: Diana Rydberg, Carl-Olav Stiller
Approved by: Karin Schenck-Gustafsson